Lord, Abbett & Co’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$122M Sell
225,799
-18,524
-8% -$9.6M 0.37% 69
2026
Q2
$132M Sell
244,323
-5,953
-2% -$3.35M 0.38% 65
2026
Q1
$148M Sell
250,276
-7,773
-3% -$3.87M 0.48% 52
2025
Q4
$126M Sell
258,049
-11,023
-4% -$5.13M 0.39% 69
2025
Q3
$113M Sell
269,072
-4,615
-2% -$1.55M 0.34% 85
2025
Q2
$78.6M Buy
273,687
+29,766
+12% +$8.9M 0.25% 109
2025
Q1
$75.2M Buy
243,921
+27,270
+13% +$9.35M 0.27% 105
2024
Q4
$76.4M Buy
216,651
+14,956
+7% +$5.5M 0.24% 113
2024
Q3
$72.3M Buy
201,695
+46,170
+30% +$15.6M 0.23% 132
2024
Q2
$49.5M Buy
+155,525
New +$41.2M 0.16% 163

Other funds holding UTHR

Lord, Abbett & Co's UTHR Position: Q3 2026 in Review

Lord, Abbett & Co reduced its United Therapeutics (UTHR) stake by 7.6% in Q3 2026, selling an estimated $9.6M and leaving 225,799 shares worth $122M. The position accounts for 0.37% of the portfolio, ranked #69.

Lord, Abbett & Co first reported a position in UTHR in Q2 2024 and has held it in 10 quarters since. The position peaked at $148M in Q1 2026. 848 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • Lord, Abbett & Co held 225,799 shares of United Therapeutics worth $122M as of Q3 2026.
  • Lord, Abbett & Co sold 18,524 United Therapeutics shares in Q3 2026, an estimated $9.6M.
  • United Therapeutics made up 0.37% of Lord, Abbett & Co's portfolio in Q3 2026, its #69 holding.
  • Lord, Abbett & Co first reported a position in United Therapeutics in Q2 2024 and has held it in 10 quarters since.
  • Lord, Abbett & Co's United Therapeutics position peaked at $148M in Q1 2026.
  • 848 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Lord, Abbett & Co's 13F filing for Q3 2026, filed 13 Nov 2026.